From the publishers of JADPRO

Biomarkers in NSCLC Resource Center

Advertisement

Last Updated: Monday, August 16, 2021

Amivantamab-vmjw given at the selected phase II dose in a phase I trial (CHRYSALIS) produced durable responses in patients with EGFR exon 20 insertion–mutated non–small cell lung cancer whose disease progressed on platinum-based chemotherapy. The findings supported the May 2021 accelerated approval of amivantamab in this setting.

Journal of Clinical Oncology
Advertisement
News & Literature Highlights
Advertisement
Advertisement